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INTRODUCTION 
 
 HIV   infection was  first documented in India in 1986 from Chennai1. 
Since then HIV has spread to all parts  of the country from the high risk 
group to the antepartum population in many states2 at an alarming rate. 
According to the NACO there are 2.3 million People Living with HIV 
infection and AIDS( PLHA) in India against the WHO  estimation of 5.2 
million2. UN AIDS estimates show that India belong  to low prevalence  
country according to the latest global report3. In 2001 National  
Behavioral Study  conducted  among 85000  people, AIDS awareness in 
India was only 75%4. It was  particularly low among rural women from  
Bihar , Gujarat  and West B1engal. Less than 33% of  all the responders 
have ever heard  of Sexually Transmitted Infections and only 21 % were 
aware of links between HIV and sexual transmission4. 
 
  With the introduction of Highly Active Anti-retroviral Therapy  the 
longevity of  life of  the HIV patients have  increased up to 50 years if  
HAART  is initiated  at an early stage of illness5 .After the introduction of 
HAART   the chronic complications of the disease and the treatment 
started appearing more ; including cancers, dyslipidemia, Insulin  
resistance , lipoatrophy, osteonecrosis, ischemic heart disease 7,8,9,10. 
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Metabolic derangements and body fat abnormalities are well 
known to occur in the course of the HIV infection , both due to direct 
course of the infection and as a complication of treatment6. 
       Various studies have addressed on the occurrence of lipodysrophy  
following HAART (Highly active Anti –Retroviral Treatment) especially 
with the use of protease inhibitors  and NNRTI. characterized by central 
obesity with peripheral wasting , hyperlipidemia , insulin resistance .2,3,4,5, 
                 Abnormalities in lipid metabolism in HIV patient are described 
before the advent of HAART.6.Increased serum Triglycerides  ,LDL 
cholesterol  and decreased  HDL cholesterol is seen in HIV patients in 
advanced disease especially in HAART treated patients6 . Abnormalities 
in body composition is seen in 40- 50 % of ambulatory patients6 .Recent  
studies have proved increased  incidence cardiovascular mortality mainly 
following  the Protease Inhibitor exposure .95. Most of these changes 
occur in response to HAART especially when viral load is markedly 
diminished .The risk increases with increasing age,  female sex  and 
duration of the drug exposure. Recent studies have shown that there is 
significant increase in cardiovascular mortality in HIV patients especially 
on PI &     NNRTI    based   HAART  therapy. 
       The aim of the study is to compare the lipid parameters in   patients 
attending ART centre who are exposed to HAART to patients not 
exposed to HAART 
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                              REVIEW OF LITERATURE 
 
BIOCHEMISTRY OF LIPOPROTENIS16,17 
 Fat absorbed form the diet and lipids synthesized by the liver and 
adipose tissue must be transported between the various tissue and organs 
for utilization and storage. Since lipids are insoluble in water, 
transporting it in an aqueous environment of blood plasma is a problem . 
This is solved by associating nonpolar lipids with amphipathic lipids and 
proteins to make water-miscible lipoproteins.  
 
 Lipoproteins are composed of lipids, proteins and small amount of 
carbohydrate. The major lipids in lipoproteins are triacylglycerols, 
phospholipids, cholesterol, cholesteryl esters and small amount of free 
fatty acids. The protein moiety of a lipoprotein is called apolipoprotein or 
apoprotein.  
 
Lipoproteins, consist of a core of cholesterylester, triacylglycerols, 
and covered by a surface monolayer of phospholipids, free cholesterol, 
and apolipoproteins. The major plasma lipoproteins-chylomicrons, very-
low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), 
low-density lipoprotein (LDL), and high-density lipoprotein (HDL) are 
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distinguished by lipid content, density on ultracentrifugation, size, 
mobility on electrophoresis, and the proteins on their surfaces. 
   
 The lipoproteins chylomicrons and VLDL are not thought to be 
atherogenic, but the remnants of their lipolysis chylomicron remnants and 
IDL, respectively are believed to be atherogenic. The atherogenicity of 
LDL, the metabolic end product of VLDL and lipoprotein(a) [Lp (a)]has 
been established, as has the cardioprotective effect of HDL. 
 
 
All nucleated cells synthesize cholesterol, but only hepatocytes and 
enterocytes can effectively excrete cholesterol from the body, into either 
the bile or the gut lumen. In the liver, cholesterol is excreted into the bile, 
either directly or after conversion to bile acids. Cholesterol in peripheral 
cells is transported from the plasma membranes of peripheral cells to the 
liver and intestine by a process termed "reverse cholesterol transport" that 
is facilitated by HDL 
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Table :1 Classification of lipoproteins 
  
LIPOPROTEI
N CLASS 
MAJOR 
LIPIDS 
APO-
LIPOPROTEINS 
SOURCE 
Chylomicron Triacylglycerol, 
phospholipids 
A-I, A-II, A-IV, B-
48, C-I, C-II, C-III, E 
Intestine 
Chlomicron 
remnants  
Cholesterylester, 
cholesterol  
B-48, E Chylomicron 
VLDL Triacylglycerol, 
Phospholipid 
B-100, C-I, C-II, C-
III, E  
Liver 
IDL Cholesteryl ester, 
Triacylglycerol 
B-100, E VLDL 
LDL Cholesterylester, 
Phospholipid 
B-100 VLDL 
HDL 2 Phospholipid, 
Cholesteryl ester 
A-I, A-II, C-I, C-II, E Liver Intestine
HDL3 Phospholipid, 
Cholesterl ester 
A-I, A-II, C-I, C-II, E Liver Intestine
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Apolipoproteins: 
 The apolipoprotiens (apos) provide structural stability to the 
lipoproteins and determine the metabolic fate of the particles upon which 
they reside. 
 
Apolipoprotein Mol. Mass 
(Dalton) 
Lipoproteins Metabolic Functions 
apo A1 28,000 HDL, 
Chylomicrons 
Structural component of 
HDL; LCAT activator   
apo AII 17,000 HDL, 
Chylomicrons 
Unknown: possibly 
facilitates transfer of 
other apos between 
HDL and chylomicrons 
apo B48 2,60,000 Chylomicrons, 
Chylomicron 
remnants 
Necessary for assembly 
and secretion of 
chylomicrons from the 
small intestine 
apo B100 5,50,000 VLDL, IDL, LDL Necessary for assembly 
and secreation of VLDL 
form the liver; structural 
protein of VLDL, IDL, 
LDL; ligand for LDL 
receptor 
apo CI 7,600 Chylomicrons, 
VLDL, HDL 
May inhibit hepatic 
uptake of chylomicron 
and VLDL receptor 
 
 
LCAT-Lecithin Cholesterol Acyl Transferase Apoprotein (a), a 
large glycoprotein that shares a high degree of sequence homology with 
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the plasma zymogen plasminogen is made by hepatocytes and is secreted 
into plasma where it forms a covalent linkage with the apo B100 of LDL 
to form lipoprotein (a). The physiologic role of lipoprotein (a) is not 
known, but elevated levels are associated with an increased risk for 
atherosclerosis. 
 
Transport of Exogenous (dietary) Lipoproteins 
    An average  individual  consumes  50 to 100 g of fat and 0.5g of 
cholesterol during three or four meals, hence  transport of dietary fats is 
essentially continual. Normolipidemic individuals dispose most dietary 
fat in the bloodstream within 8h of the last meal, but some individuals 
with dyslipidemia, particularly those with elevated fasting levels of 
VLDL triglyceride, have measurable levels of intestinally derived 
lipoproteins in the circulation as long as 24h after the last meal. 
 
 In the intestinal mucosa dietary triglyceride and cholesterol are 
incorporated into the core of nascent chylomicrons. The surface coat of 
the chylomicron is composed of phospholipids, free cholesterol, apo B48, 
apo AI, apo AII and apo AIV. The chylomicron , essentially a fat droplet 
containing 80 to 95 percent triglycerides, is secreted into lacteals and 
transported to the circulation via the thoracic duct. In the plasma apo C 
proteins are transferred to the chylomicron from HDL. apo CII is required 
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for hydrolysis of triglycerides by lipoprotein lipase (LPL) on capillary 
endothelial cells in fat and muscle, and apo CIII may modulate core 
triglyceride hydrolysis by regulating LPL activity. As a consequence, 
dietary triglyceride is delivered to adipocytes and muscle cells as fatty 
acids, and dietary cholesterol is taken up by the liver where it can be used 
for bile acid formation, incorporated into membranes, resecreted as 
lipoprotein cholesterol back into the circulation, or excreted as cholesterol 
into bile. Dietary cholesterol also regulates endogenous hepatic 
cholesterol synthesis. 
 
 Abnormal transport and metabolism of chylomicrons may 
predispose to atherosclerosis, and their remnants can be taken by cells of 
the vessel wall, including monocyte-derived macrophages that migrate 
into the vessel wall from plasma. Cholesteryl ester accumulation by these 
macrophages transforms them into foam cells, the earliest cellular lesion 
of the atherosclerotic plaque. If the postprandial levels of chylomicrons or 
their remnants are elevated or if their removal from plasma is prolonged, 
cholesterol delivery to the artery wall may be increased. 
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Transport of Endogenous Lipids 
 The endogenous lipid transport system conveys lipids from the 
liver to peripheral tissues and from peripheral tissues back to the liver. In 
the liver, triglycerides are made from fatty acids that are either taken up 
from plasma or synthesized de novo within the liver. Cholesterol can also 
be synthesized by the liver or delivered to the liver via chylomicron 
remnants. These core lipids are packaged together with apo B100 and 
phospholipids into VLDL and secreted into plasma where apos CI, CII, 
CIII and E are added to the VLDL particles.  
 
Triglycerides make up the bulk of the VLDL (55 to 80 percent by 
weight), and the size of the VLDL is determined by the amount of 
triglyceride available. Hence, very large triglyceride-rich VLDL is 
secreted in situations where excess triglycerides are synthesized, such as 
states of caloric excess,  diabetes mellitus, and with alcohol consumption. 
Small VLDL is secreted when fewer triglycerides are available.  
 
Although VLDL is normally the principal hepatic lipoprotein 
secreted by most individuals, VLDL and cholesteryl ester-enriched IDL-
like particles may be secreted by the liver in individuals with combined 
hyperlipidemia. Smaller, more dense VLDL particles are efficiently 
converted to LDL, and apo E in the VLDL remnants is the ligand that the 
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binds the remnants to the LDL receptor for removal from the plasma. apo 
B100 is the only protein remaining on the surface of the LDL particle.  
 
 The half-life of LDL in plasma is determined principally by the 
availability (or ‘activity’) of LDL receptors (apo B100, apo E). Most 
plasma LDL is taken up by the liver, and the remainder is delivered to 
peripheral tissues, including the adrenals and gonads which utilize 
cholesterol as a precursor for steroid hormone synthesis. The adrenals 
have the highest concentration of LDL receptors per cell in the body. The 
LDL receptor, a glycoprotein with a molecular mass of approximately 
160kDa, is present on the surface of nearly all cells in the body. Goldstein 
and Brown characterized the molecular genetics and cell biology of the 
LDL receptor and defined its role in the cholesterol metabolism. While 
the LDL receptor is a major factor in determining plasma LDL 
cholesterol levels, the rates of entry of VLDL into plasma and the 
efficiency with which VLDL is converted to LDL also influence steady-
state LDL concentrations in plasma. Increased levels of plasma LDL 
cholesterol and apo B100 are risk factors for atherosclerosis. Normal 
LDL does not cause foam cell formation when incubated with cultured 
macrophages or smooth-muscle cells, but when LDL undergoes lipid 
peroxidation it becomes a ligand for an alternative, scavenger receptor 
pathway. Scavenger receptors are present on endothelial cells and 
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macrophages, uptake of modified (oxidized) lipoproteins by these 
receptors in macrophages results in formation of cholesterol-laden foam 
cells. In addition to foam cell formation, oxidized LDL acts in the vessel 
wall to stimulate the secretion of cytokines and growth factors by 
endothelial cells, smooth-muscle cells, and monocyte and proliferation of 
smooth-muscle cells which synthesize and secrete increased amounts of 
extracellular matrix such as collagen.  
 
 The role of VLDL in atherogenesis is uncertain. The major reason 
for this uncertainty derives from the inverse relationship between 
elevated levels of triglyceride-rich lipoproteins and reduced levels of the 
antiatherogenic HDL cholesterol and it is possible that 
hypertriglyceridemia may not be directly atherogenic but the surrogate of 
other lipoprotein abnormalities. It is clear that cholesteryl ester-enriched 
VLDL cause foam cell formation. Thus the risk of atherosclerosis from 
hypertriglyceridemia and elevated VLDL levels may be determined by 
the level of cholesteryl ester-enriched VLDL remnants within the plasma. 
The atherogenic potential of IDL is probably similar to that of VLDL 
remnants.    
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LIPOPROTEIN SUBFRACTIONS AND ATHEROSCLEROTIC 
HEART DISEASE11 
Hypercholesterolemia 
 The dyslipidemia clearly associated with increased risk for CAD is 
hypercholesterolemia, particularly elevated plasma levels of cholesterol 
carried in LDL. LDL contains approximately 70 percent of cholesterol in 
the blood and is the primary target of intervention in the guidelines of the 
third adult treatment panel of the NCEP. 
 
 
LDL 
 Small, dense low-density lipoprotein, in addition to LDL 
cholesterol level, LDL composition influences CAD risk. Small, dense 
LDL frequently occurs in conjunction with elevated triglyceride level, 
low HDL cholesterol level, truncal obesity, and hypertension. LDL 
subclass pattern can be altered to a potentially less atherogenic pattern by 
pharmacological therapy with gemfibrozil ,for example, has been shown 
to shift LDL particles toward a larger, more buoyant species. The 
mechanism by which small, dense LDL causing increased atherosclerotic 
risk has not been totally determined and may be a combination of 
mechanisms. Compared with large, buoyant LDL, small, dense LDL has 
a lower sialic acid content, which may increase the binding capacity of 
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LDL for proteoglycans localized to the arterial wall. Hemostatic variables 
may be shifted to a more atherogenic pattern in the presence of small, 
dense LDL. A dose dependent increase in thromboxane synthesis has 
been reported with increasing density of LDL particles. Small, dense 
LDL appears to be more susceptible to in vitro oxidation than large, 
buoyant LDL. There is overwhelming evidence for reductions in coronary 
events and cardiovascular mortality with lowering of low-density 
lipoprotein cholesterol (LDL-C). 
 
Oxidized LDL 
  LDL may be oxidized as a result of exposure to endothelial cells, 
smooth muscle cells, or macrophages. Oxidized LDL attracts circulating 
monocytes, which then adhere to the arterial wall, prevented from leaving 
the arterial wall scavenger receptors on macrophages recognize and bind 
oxidized LDL and intracellular cholesterol accumulates. As uptake 
continues, the macrophages can become lipid-laden foam cells, the 
components of the fatty streak, which is the precursor atherosclerotic 
lesion. 
 
Triglycerides (TG) 
       The Adult Treatment Panel III guidelines suggest that because 
elevated TGs are an independent CAD risk factor, some TG-rich 
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lipoproteins, commonly called remant lipoproteins, must be atherogenic. 
A number of studies have shown that in type 2 diabetes, the severity of 
CAD is positively related to the numbers of TG-rich particles in the 
plasma17. triglycerides are causally related to the progress of 
atherogenesis. They are a significant risk factor for CAD in females than 
males. They continue to be predictors of CAD in both men and women 
above 65 years18. 
 
HDL 
 Plasma levels of high-density lipoprotein-cholesterol (HDL-C) are 
a powerful independent cardiovascular risk factor, bearing an inverse 
relationship with atherosclerotic cardiovascular disease. Apart from its 
protective role in atherosclerosis, HDL-C increased fibrinolysis, is an 
antioxidant to low density lipoprotein-cholesterol (LDL-C), and decreases 
platelet aggregation. In particular, HDL carries excess cholesterol from 
peripheral cells to the liver for removal in the process termed reverse 
cholesterol transport, reduces oxidative modification of low-density 
lipoproteins (LDL), and inhibits cytokine-induced expression of cellular 
adhesion molecules on endothelial cells. Studies of the newly described 
adenosine triphosphate-binding cassette protein A1 (ABCA1) transporter 
have established a crucial role for this transporter in modulating the levels 
of plasma HDL and intracellular cholesterol in the liver as well as in 
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peripheral cells20. Up to a third of patients with atherosclerotic 
cardiovascular disease have ‘desirable’ plasma levels of total cholesterol 
but low HDL-C levels21. 
 
Metabolic Complications of HIV Infection 
 Metabolic complications, including dyslipidemia, insulin resistance 
and altered fat distribution (loss of subcutaneous fat and a relative 
increase in central fat), are common in adults infected with HIV which is 
more pronounced in patients receiving HAART6. These complications 
may increase these patient’s risk of cardiovascular disease. 
  
Dyslipidemia in HIV 
 Alterations in serum lipid values have been widely reported among 
persons infected with HIV. Longitudinal assessment of patients with HIV 
seroconversion suggests that there are decreases in total, HDL and LDL 
cholesterol and increase in triglycerides (TG) and VLDL, before 
treatment6,12,13. Sharon. A. Riddler et al., reporting the results of serum 
lipid levels in 50 HIV positive treatment-naïve patients noted a decline in 
mean total cholesterol (TC) by 30 mg/dL HDL-C by 12 mg/dL and LDL-
C by 22 mg/dL compared to preseroconversion values 13. Early studies 
also shown an increase in plasma free fatty acids and a decrease in 
apolipoproteins A-1 and B-10023. 
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Pathogenesis of Dyslipidemia in HIV 
 Various  studies on HIV patients  suggested that factors contributing  to 
dyslipidemia were increased apo E levels, increased hepatic synthesis of 
VLDL and decreased clearance of TG13,23, 24. Dyslipidemia may also be 
due in part to the effect of viral infection, acute phase reactants, 
circulating cytokines including interferon α (INF α)25.      
 
 Increased rates of VLDL-TG secretion during both fed and fasted 
condition contribute to hypertriglyceridemia associated with HIV 
infection13. Hepatic fatty acid availability is the major regulator of 
VLDL-TG secretion26. It is likely that the increased basal rate of fatty 
acid release from subcutaneous adipose tissue stimulates the increase in 
basal VLDL-TG secretion. HIV infection itself rather than HAART was 
responsible for the alterations in fatty acid metabolism, because basal 
glycerol kinetics, an index of adipose lipodystrophy whether  receiving 
HAART or not21. It is possible that the greater basal lipolytic rate was the 
result of increased beta-adrenergic stimulation of adipose tissue13. To 
support this view, it was found that plasma and urinary catecholamines 
were increased in subjects with HIV6,28 .  
 
In addition, increased beta-adrenergic stimulation is responsible for 
increased basal lipolytic rates in other inflammatory diseases, such as 
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cancer29. Increased rates of hepatic denovo lipogenesis have been 
observed in patients with HIV infection. Therefore it is likely that 
increased hepatic fatty acid availability and increased denovo lipogenesis 
contributed to high VLDL-TG secretion30. Plasma clearance of VLDL-
TG was lower in men with HIV dyslipidemia than is healthy men during 
both basal conditions and fed state. The reduced rate of clearance may be 
related to alterations in lipoproteinlipase activity associated with HIV 
infection or HAART31,32. This also contributes to the high VLDL-TG in 
HIV infection. 
 
      Infections are well known to cause metabolic alterations as a part 
of direct effect of the infection, via release of acute phase reactants and 
cytokines33. Of these, cytokines – especially INF- α was found to have 
strong association with dyslipidemia in HIV.14,20 Grunfeld.C. et al 
reported significant elevation of serum INF- α in patients with HIV 
positively and AIDS. There was significant correlation between INF- α 
levels and serum TG level. These studies suggest that INF- α, which has 
previously been shown to modulate lipid metabolism in vitro and invivo 
may be responsible for the hypertriglyceridemia found in AIDS.  
C-reactive  protein levels were increased in AIDS, but tumor necrosis 
factor and haptoglobulin levels were not15. 
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Dyslipidemia in HIV patients on HAART 
 Dyslipidemia has also been associated with the use of HAART but 
of a different pattern from that of treatment naïve patients. Protease 
inhibitors have been mostly implicated but other class of drugs nucleoside 
reverse transcriptase inhibitors also were found to alter lipid profile. 
There is an increase in total cholesterol, TG, LDL-C, VLDL, lipoprotein 
(a), and apolipoprotein B which occur independently of HIV infection 
10,34. Protease inhibitors interfere with cholesterol synthesis, by inhibition 
of the proteasome, which regulates apolipoprotein B production. It also 
inhibits sterol regulatory enhancer-binding protein-1 (SREBPI) causing 
increased hepatic lipid production 35,36. Dyslipidemia may also be a 
consequence of insulin resistance, of visceral fat accumulation and of 
lipoatrophy with release of stored lipids and an inability to take up 
circulating TG.  
  
Protease inhibitor and efavirenz  induce  lipoatrophy   by inhibiting 
SREBP1 ( Sterol regulatory enhancer binding  protein) which mediates 
activation of Retnoid X receptor, PPARÝ coactivator 16. Except 
Atezenavir all Protease inhibitors cause lipodystrophy and dyslipidemia. 
As a result of metabolic complications of PI  based regimes they  are now 
used on failure of NRTI   based regimes 95 API 
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Friis-Møller et al., reporting the results of a large cross-sectional 
study, noted that  hypercholesterolemia( more than 240 mg /dl) in 27 
percent of subjects receiving combination therapy that included a 
protease inhibitor, 23% receiving nonucleosidereverse-transcriptase 
inhibitor, and 10% receiving only nucleoside reverse-transcriptase 
inhibitors, as compared with 8 % among the  previously untreated 
subjects. The corresponding percentages for hypertriglyceridemia ( more 
than 200/dl). were 40, 32, and 23 percent, as compared with 15 percent 
among previously untreated subjects. 
 
Low levels of high-density lipoprotein (HDL) cholesterol(< 35 mg 
per /dl  were reported in 27, 19, and 25 percent of the subjects, 
respectively, as compared with 26 percent of those who were previously 
untreated .Among patients with evidence of body-fatabnormalities,57 
percent had triglyceride levels above 200 mg/dl, and 46 percent had HDL 
cholesterol levels below 35 mg /dl , as compared with 9 and 17 percent of 
healthy subjects matched for age and body-mass index from the 
Framingham Offspring Study cohort. 
 
For cholesterol levels above 200 mg /dl , the prevalence rate in the 
HIV-infected group was 57%, as compared with 42 % in the Framingham 
control  group. 
20 
 
 
Nucleoside   analogues   causes   lipoatrophy    and     dyslipidemia    
by  mitochondrial injury  resulting from inhibition of mitochondrial     
DNA polymerase of  adipocytes. They also inhibit   adipogenesis & 
adipocyte differentiation  promote lipolysis  and excretes  synergistic 
toxic effect of protease inhibitor6.Efavirenz based regimes have shown  
more dyslipdemias and  cardiovascular risk compared to nevirapine based 
regimes. Leonardo Calza; Roberto Manfredi;  and et al proved this in 
their study  Nevirapine is a better substitution for efavirenz in PI based 
regimes. 
 
Storage of  increased circulating fatty acids ,impaired fatty acid 
oxidation contribute to intra myocellular fat accumulation , insulin 
resistance  and hepatic steatosis6. 
 
Body fat abnormalities and lipodystrophy in HIV 
 Abnormalities in body composition have been reported in 40 to 50 
percent of ambulatory HIV infected patients and the proportion is greater 
in those receiving HAART11,36,37. Prevalence rates vary widely from 11 to 
83 percent in cross-sectional studies.39,40   
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 Lipoatrophy rates may be even higher depending on the 
characteristics of the cohort (sex, age, and possibly race), the type and 
duration of HAART, and the comparison population.41 Definitions of 
clinically significant loss of subcutaneous fat and gain in truncal fat have 
not yet been established. A preliminary case definition based on data 
obtained by dual energy X-ray absorptimoetry (DEXA) and computed 
tomography was validated in a prospective study but is not yet 
recommended for use in clinical practice.41  
 
 Subcutaneous lipoatrophy and relative or absolute accumulation of 
central fat may occur in HIV infected patients. Subcutaneous lipotrophy 
is most noticeable in the face, limbs and buttocks but can also occur in 
the trunk.42 Central fat accumulation, when present, most often represents 
the accumulation of visceral fat. Total abdominal fat accumulation may 
vary and may occur independently of peripheral fat loss.41 Fat 
accumulation may also be found within the breast and over the 
dorsocervical spine resulting in ‘buffalo hump’, in lipomata and within 
the muscle and liver. This pattern of peripheral lipoatrophy and central 
lipohypertrophy result in increased waist hip ratio (WHR). 
 Prospective studies investigating body composition in patients 
starting antiretroviral treatment for the first time have demonstrated initial 
increase in limb fat during the first few months of therapy, followed by a 
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progressive decline during the ensuing three years44,45. In contrast, truncal 
fat, increases initially and then remain stable during the ensuing two to 
three years, resulting in relative central adiposity. Changes in limb and 
central fat masses are clinically evident in 20 to 35 percent of patients 
after 12 to 24 months of HAART46,47. 
 
Pathogenesis of Lipodystrophy 
 Changes in body composition have been reported in a limited 
number of patients who have never received HAART, but most changes 
occur in response to HAART when the viral load is markedly diminished. 
  
It is less likely that the syndrome is a direct effect of HIV. 
Lipodystrophy is almost exclusive to patients receiving HAART. Also 
visceral fat accumulation and lipotrophy can improve after protease 
inhibitor and nucleoside – reverse transcriptase inhibitor switching, 
without changes in viral load.10 Also most cohorts have found either a 
negative association between increasing HIV RNA and lipodystrophy or 
no association at all.   
 
 The type, duration and current use or non use of HAART are 
strongly associated with severity of lipoatrophy. Combination therapy 
based on the use of two nucleoside analogue reverse transcriptase 
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inhibitors and a protease inhibitor is especially strongly associated with 
severe lipoatrophy.43  
 
 Protease inhibitors may induce lipotrophy by inhibiting SREBPI- 
mediated activation of the heterodimer consisting of adipocyte retinoid X 
receptor and peroxisome proliferators activated receptor γ (PPAR γ) or 
related transcription factors such as PPAR γ coactivator 134.,35. Invitro 
studies have demonstrated that protease inhibitors can inhibit lipogenesis 
and adipocyte differentiation, stimulate lipolysis, and impair SREBPI 
nuclear localization.47 
 
 The nucleoside analogue linked most strongly to lipoatrophy is 
stravudine, particularly when used in combination with didanosine.14,43 
Lipoatrophy associated with nucleoside analogues may be due in part to 
mitochondrial injury resulting from inhibition of mitochondrial DNA 
polymerase γ within adipocytes49 and depletion of mitochondrial DNA50, 
although the extent and specificity of this effect remains unknown. 
Nucleoside analogues can inhibit adipogensis and adipocyte 
differentiation51, promote lipolysis and exert synergestic toxic effects 
with those of protease inhibitors invitro and invivo52,53. 
 
24 
 
 Older age, lower body weight before therapy, prior diagnosis of 
AIDS, and a lower nadir CD count are associated with lipoatrophy. 
Central fat accumulation may be more common among women than 
among men.54 Storage of increased circulating fatty acids, impaired fatty 
acid oxidation, or both may contribute to increased intra-cellular lipid 
content, hepatic steatosis and insulin resistance.55,56.57 
 
 Apart from lipodystrophy, generalized wasting can occur in HIV 
infection. Generalized wasting is an AIDS defining condition. It is 
defined as involuntary weight loss of more than 10% associated with 
intermittent or constant fever and chronic diarrhea or fatigue lasting more 
than 30 days in the absence of a defined cause other than HIV infection. 
A constant feature of this syndrome is severe muscle wasting with 
scattered myofibre degeneration and occasional evidence of myositis.58 
 
Insulin resistance and abnormal glucose homeostasis 
 Hyperinsulinemia, a surrogate measure of insulin resistance, is 
commonly seen in association with excess truncal fat, loss of fat in the 
limbs, an increased waist-to-hip ratio, and a buffalo hump 96. Among HIV 
infected adults with lipoatrophy or fat accumulation, diabetes mellitus 
was seen in 7.0 percent, as compared with 0.5 percent of otherwise 
healthy control subjects matched for age and body-mass index by  Carr  
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et al10. Impaired glucose tolerance was present in more than 35 percent of 
HIV infected subjects compared with 5 percent of otherwise healthy 
control subjects matched for age and body mass index. In a longitudinal 
cohort study, diabetes mellitus was 3.1 times as likely to develop in HIV 
infected men receiving combination antiretroviral therapy as it was in 
control subjects over a three year period of observation. The rate at which 
impaired glucose tolerance and insulin resistance in HIV infected adults 
progress to overt diabetes mellitus is not known.10 
 
Pathogenesis 
 Antiretroviral therapy may lead to altered flux of substrates, 
including free fatty acids, as well as accumulation of intramyocellular 
lipid, alterations in adipokine levels (e.g., a low level of adiponectin), and 
reduced PPAR gamma expression in subcutaneous adipocytes; 
antiretroviral therapy may also contribute to altered glucose 
homeostasis.60 Protease inhibitors have been shown to induce insulin 
resistance in vitro by reducing glucose transport mediated by glucose 
transporter 4 61, without affecting postreceptor insulin signalling. The 
results of clinical studies have suggested that indinavir and lopinavir have 
short-term adverse effects on insulin sensitivity62,63. Delayed but long-
term effects, possibly related to changes in body composition, may affect 
insulin sensitivity63,62. Protease inhibitors may also reduced pancreatic 
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beta-cell insulin secretion,64 but insulin resistance is the primary defect. 
Direct effects of nucleoside analogues on glucose metabolism have not 
been demonstrated, but such drugs may contribute to insulin resistance 
indirectly through changes in fat distribution. 
 
Clinical Consequences of Metabolic and Body Fat Abnormalities 
 Metabolic complications, including dyslipidemia, insulin 
resistance, and altered fat distribution (loss of subcutaneous fat and a 
relative increase in central fat), are common in adults infected with the 
human immunodeficiency virus (HIV). These complications may increase 
these patients risk of cardiovascular disease. The chief risk associated 
with markedly increased triglyceride levels is pancreatitis.6 
Lipodystrophy can lead to issues of cosmetics and stigmatization. 
 
Cardiovascular Disease 
 Soon after the introduction of protease inhibitors and non-
nucleoside reverse-transcriptase inhibitors for the management of human 
immunodeficiency virus (HIV) infection, clinicians observed unexpected 
cardiovascular events among patients receiving these new, combination, 
“highly active” antiretroviral regimens. Angina, myocardial infarction, 
and stroke were seen in patients who were relatively young. Providers 
became suspicious that these events were related either to chronic HIV 
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infection, since patients were surviving for longer periods than they had 
in the past, or to the new anti-HIV regimens, which are associated with 
substantial metabolic abnormalities35,36.               
 
 The Kaiser Permanente Medical Care Program of Northern 
California compared rates of hospitalization for coronary artery disease 
and reported that the rate of such hospitalizations among HIV-infected 
patients, regardless of whether they used antiretroviral agents, was 1.5 
times that among their uninfected counterparts.65 Thus, an emerging body 
of evidence suggested that as HIV-infected patients were living longer as 
a result of antiretroviral therapy, cardiovascular disease was developing at 
unexpected rates.  
 
 Friis-Moller and collaborators present data from the prospective, 
multinational Data Collection on Adverse Events of Anti-HIV Drugs 
(DAD) Study. This study collected data on more than 24,400 patients 
enrolled in 11 previously established cohorts in Europe, the United States, 
and Australia. Atherosclerotic events were prospectively identified and 
independently validated60. Over a median follow-up time of 1.6 years 
through February 2002, 126 patients had a myocardial infarction. 
Including in their analysis the cumulative duration of drug exposure, the 
authors determined that during the first four to six years of combination 
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therapy, there was a 16 percent relative increase in the rate of myocardial 
infarction per year of exposure to antiretroviral drugs. 
 
 DAD study group  (Phase II) in same  cohort of HIV   patients their 
reported  a significant increase in death due to cardiovascular disease  .  
The study showed 346 death  due to cardiovascular disease with 
incidence of  3.45% compared to 1.4% in  the matched controls.  It must 
be recognized that as HIV infected patients live longer, their risk of 
cardiovascular disease, compounded by their preexisting burden of 
traditional risk factors, inevitably increases. Hypercholesterolemia, older 
age, smoking, diabetes mellitus, male sex, and a prior history of 
cardiovascular disease were also associated with an increased risk of 
myocardial infarction.65 Some cardiovascular events may have been a 
consequence of HIV infection, of antiretroviral therapy, or of a 
synergistic relation among all these risk factors. 
 
Mechanisms of Cardiovascular Disease 
 Is it plausible that HIV infection itself could promote 
atherosclerosis through a pro-inflammatory effect on endothelial cells, 
much like the mechanism that has been hypothesized for other infectious 
agents such as cytomegalovirus, herpes simplex virus, or Chlamydia. HIV 
infection promote cardiovascular disease indirectly, by way of the lipid 
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abnormalities it induces and due to the various drugs. The acquisition of 
HIV infection is associated with reductions in the HDL cholesterol level 
as well as reductions in the total cholesterol and low-density lipoprotein 
cholesterol levels. 
 
 Hypertriglyceridemia is associated with disease progression and 
HIV viremia.66 Hsue et al. reported increased carotid intima-media 
thicknesses and increased rates of progression over a one-year period in 
HIV infected adults with a mean age of 45 years as compared with age 
and sex-matched uninfected controls. Increased thickness of the carotid 
intima-media was associated with traditional risk factors, including 
hypertension, hypercholesterolemia and smoking.66 When assessed by 
electron beam computed tomography, coronary-artery calcifications have 
been shown to be more common in patients with HIV infection that in 
uninfected patients. Increased tissue levels of plasminogen activator and 
plasminogen activator inhibitor 1 suggest that fibrinolysis is impaired in 
HIV infected patients.  
 
 Is it plausible that the antiretroviral drugs themselves promote 
atherosclerosis directly or indirectly. Endothelial dysfunction and reduced 
flow-mediated dilation in association with increased atherogenic 
lipoproteins have been reported among HIV infected adults receiving 
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protease inhibitors69, hypertension is more common in HIV infected 
patients treated with protease inhibitors, nonnucleoside reverse 
transcriptase inhibitors, or both then in patients who have never received 
antiretroviral therapy and is associated with increased body-mass index 
among HIV-infected patients70.  
 
Much attention has been paid to the metabolic disturbances 
attributed to these drugs, which could indirectly promote atherosclerosis. 
High levels of protease inhibitors may promote the formation of 
atherosclerotic lesions by increasing CD36 dependent cholesterol ester 
accumulation in macrophages, a scavenger-receptor pathway that is 
thought to mediate the formation of atherosclerotic lesions.71 
 
 In addition, certain antiretroviral agents are associated with insulin 
resistance. HIV infected patients receiving antiretroviral therapy have 
also experienced changes in body habitus (lipodystrophy) that have 
themselves been associated with cardiovascular disease. Thus, treated 
patients may have lipodystrophy, diabetes, and atherogenic lipid profiles, 
which could be the routes by which these drugs cause premature 
atherosclerosis, perhaps in concert with direct toxic effects on the 
endothelium. Taken in aggregate, the weight of the evidence suggests that 
HIV infected patients treated with combination antiretroviral regimens 
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are at increased risk for the development of premature atherosclerotic 
complications. 
 
 To summarize. The mechanisms of vascular in HIV-infected 
patients are not completely known but may relate to dyslipidemia, insulin 
resistance, diabetes mellitus, inflammation, impaired fibrinolysis, factors 
specific to antiretroviral medications, or combinations of these factors. 
 
Pancreatitis 
 Elevations in TG associated with advanced HIV or associated with 
HAART have been reported to cause serious pancreatitis, but this has 
been less well reported in literature.72,73 
 
Assessment of Metabolic and Body-Fat Abnormalities  
Dyslipidemia 
 In all HIV infected adults, fasting lipid levels should be measured 
annually before antiretroviral therapy is initiate, and within one to two 
months after any change in the antiretroviral regimen.95 It is important to 
determine whether there is a family history of dyslipidemia or diabetes 
and to assess the patient’s use of alcohol and of medications known to 
alter lipid levels (e.g., estrogen). Whenever possible, the antiretroviral 
medication least likely to worsen lipid levels should be selected for 
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patients with dyslipidemia. The chief risk associated with markedly 
increased triglyceride levels is pancreatitis. 
 
Abnormal glucose homeostasis 
 In HIV infected patients, fasting glucose levels should be 
determined before antiretroviral therapy is initiated and should be 
determined annually as well as within a few weeks after any change in 
the antiretroviral regimen. Weight, the severity of fat distribution 
abnormalities, and medication history should all be assessed, as should 
the family history, for the presence of diabetes mellitus. Impaired glucose 
tolerance and insulin resistance are likely to be present for a variable 
period before overt diabetes mellitus develops.  
 
Impaired glucose tolerance and hyperinsulinemia are considered 
cardiovascular risk factors in adults without HIV infection. Thus, an oral 
glucose-tolerance test or measurement of the fasting insulin level should 
be considered in HIV infected patients with other cardiovascular risk 
factors or a family history of type 2 diabetes mellitus. 
Body-Fat Abnormalities 
 Annual assessment of body fat is recommended for adults who 
begin combination antiretroviral therapy that includes two nucleoside 
analogues or a protease inhibitor, as well as for any patients who switch 
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antiretroviral agents. Dual-energy x-ray absorptiometry is useful for 
assessing fat in the limbs over time. Anthropometric measurements of 
truncal and limb fat, including measurement of waist, hip, and thigh 
circumferences, may provide additional information about cardiovascular 
risk. CT scanning provides information about abdominal subcutaneous 
and visceral fat. But it is associated with radiation exposure and should 
not be used clinically for this purpose. No technique has been validated 
for the assessment of facial lipoatrophy. 
 
Risk Assessment and Treatment Options 
Risk-Factor Modification 
 All potential cardiovascular risk factors, including dyslipidemia, 
insulin resistance, hypertension, smoking, sedentary lifestyle, weight and 
family history, should be assessed. It is recommended that dietary and 
lifestyle alterations, including appropriate interventions for smoking and 
hypertension, be initiated first; subsequently, therapy with lipid-lowering 
medications for hyperlipidemia or changes in antiretroviral therapy can 
be begun, when clinically possible. Insulin-sensitizing agents are 
recommended for patients with diabetes mellitus and should be 
considered for those with marked insulin resistance.    
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 Risk factor modification must balance the risk of progression of 
HIV disease against the potential risk of progression of cardiovascular 
disease with long-term maintenance of antiretroviral therapy. Although 
the risk of cardiovascular disease is increasing among HIV infected 
patients, it is still low and is unlikely to outweigh the substantial benefits 
of appropriate administration of antiretroviral medications. 
Cardiovascular risk may be a lesser concern for patients with advanced 
HIV disease and those with HIV disease that is resistant to antiretroviral 
drugs. However, in planning risk modification strategies, clinicians may 
do well to consider effective antiretroviral agents with the lowest 
propensity to increase glucose or lipid levels. 
 
Lipid-Lowering Drugs 
 In general, statins (HMG CoA reductase inhibitor) should be used 
to treat isolated hypercholesterolemia, and a fibrate should be used to 
treat isolated hypertriglceridemia. Combined statin-fibrate therapy can be 
considered when the response is incomplete, provided that there is 
appropriate safety monitoring, including periodic measurement of 
creatine kinase and aminotransferase levels.74,75,76 
 Until more specific recommendations become available, National 
Cholesterol Education Program guidelines should be used when lipid-
lowering therapy is initiated in HIV-infected patients. Drug interactions, 
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especially between specific protease inhibitors and statins, should always 
be considered.76  
 
Insulin Sensitizing Drugs 
 In HIV infected adults with central obesity and hyperinsulinemia, 
metformin (500mg twice daily) improved insulin sensitivity and 
decreased visceral adiposity, levels of cardiovascular risk markers (tissue 
plasminogen activator and plasminogen-activator inhibitor 1) and blood 
pressure. Rosiglitazone cannot be recommended for general treatment of 
lipoatrophy at this time, but it may be useful in patients with insulin 
resistance76,79 
 
Growth Hormone 
 Growth hormone levels are reduced in HIV infected men who have 
excess visceral adiposity and growth hormone secretagogues (including 
growth hormone-releasing hormone) may prove useful for increasing 
growth hormone levels to within the physiologic range and for restoring 
the distribution of body fat toward normal81-85 
 
Surgery and Other Strategies to Restore Body Contours 
 Injection of various agents has been investigated as therapy for 
facial lipoatrophy. The most widely used is polylactic acid, a resorbable 
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molecule that promotes collagen formation and appears to improve the 
appearance of facial soft tissue, with few complications.89 Surgery 
(excision or liposuction) has been performed on some patients who have 
marked dorsocervical fat accumulation, although fat may reaccumulate 
within a few months. 
 
Changes in Antiretroviral Therapy 
 Cessation of therapy with the stavudine or zidovudine generally 
leads to substantial improvements in limb fat mass. However, if another 
drug is not substituted, virologic failure is likely. Replacement of a 
protease inhibitor with nevirapine, efavirenz, or abacavir can effectively 
reduce total cholesterol,90-93 LDL cholesterol, and triglyceride levels and 
increase HDL cholesterol levels. Limited data suggest that insulin 
resistance may also improve in response to replacement of a protease 
inhibitor by nevirapine. Protease-inhibitor cessation has not been shown 
to improve lipoatrophy.91 
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                               AIMS AND OBJECTIVES 
 
 
1. To determine the prevalence of  dyslipidemia in HIV patients on  
HAART therapy & compare the various lipid fractions  with that of 
age matched  HIV patients not on therapy 
 
2. To assess the anthropometric parameters of HIV   patients on 
HAART to those not on    HAART 
 
3. T o compare lipid parameters   between the individual drug groups 
 
4. To evaluate the importance of Fasting lipid profile estimation as 
the part  of initial evaluation of HIV positive patients before 
starting HAART 
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MATERIAL AND METHODS 
 
Setting :  Young adult HIV patients of age from 20-45 years  who 
were attending ART Centre GRH Madurai & HIV  patients  
admitted in medical wards GRH Madurai  
Collaborating Department -  Anti retroviral therapy centre   Madurai  
Medical College Madurai 
  
 Design of study   –  Cross -sectional study 
 Period of study   -   1 year 
 Sample size         -  126 
 Ethical committee approval – Obtained 
 Consent   -  Informed consent obtained 
 Financial Support  –  nil 
 Conflict of interest  -  nil 
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SELECTION & DETAILS OF   STUDY SUBJECTS  
 
In   this study 126 you  patients who were attending the Antiretroviral 
therapy centre GRH Madurai & Medicine wards were included randomly. 
   
Inclusion criteria 
1. Patients selected  in random attending ART centre 
2. Age group 20 – 45 
3. HIV infection confirmed by Triple ELISA testing 
4. HAART treatment Groups by Patients on treatment more than 2 
years. 
 
Exclusion Criteria 
1. Diabetic patients 
2. Nephrotic  range proteinuria  
3. Overt Hypothyroidism 
4. Patients on drugs : Antihyperlipidemic  Drugs:, Thiazides, 
Steroids, Beta blockers 
5. Patients with liver disease 
6. Patients who are diagnosed as hypertensive / CAD before initiating 
therapy 
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Age group of 20- 45 years were selected because by 20 years a 
person attains adult anthropometric proportions  and remains more or less    
static until around 45 years  after which age related changes occur 
especially in the waist circumference and waist hip ratio94. The triple 
ELISA testing  according to NACO Guidelines was used for diagnosis  
for  HIV  infection .The total number of the patients screened were 142 of  
which 16   patients were excluded were included in the study. 
 
Patients included in the study were divided into 5 groups 
Group -1Patients  on  D4T +3TC+NVP - ( No of patients :13) 
Group -2  Patients on D4T+3TC+EFV   ( No of  patients :25) 
Group -3 Patients on ZDV+3TC +NVP    (No of patients :18)  
Group- 4 Patients on  D4T + 3TC + EFV ( N o of patients :17) 
Group -5.Patients not on HAART             ( No of patients :53) 
 
Data  
A Performa  was filled up for each patient which included   age, 
relevant history  of smoking , alcoholism , hypertension  IHD, Cerebro 
vascular  accident, peripheral vascular disease   Detailed examination was 
done including anthropometric measurements. The height was measured 
barefoot  in meters and weight ( kilogram) in normal indoor clothing. 
Waist circumference was measured as the narrowest measurement 
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between the ribcage and iliac crest .Hip circumference was measured as 
the largest measurement of the hip over the buttocks.  Waist hip ratio was 
calculated and Blood pressure was recorded with standard mercury 
sphygmomanometer .The lipid profile estimation was done in ERBA -XL 
300 Automatic analyzer.  
 
Estimation of Low density lipoproteins 
 The LDL cholesterol was estimated by the validated Friedwald 
formula. The formula hinges on the assumption that VLDL-C is present 
in concentration equal to 1/5th that of the Triglyceride concentration.13 
This assumption is valid for triglyceride levels less than 400mg/dl: 
thereafter, inconsistencies in the VLDL triglyceride/ cholesterol ratio 
occur, and the formula cannot be used. 
 
LDL cholesterol = Total cholesterol – (HDL cholesterol + 
Triglycerides/5) The collected data was analyzed  using Epidemiological 
Information Package (EPI 2002) developed by Centre for Disease Control 
(CDC) Atlanta in collaboration with WHO Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative 
variables. 
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                        RESULTS AND OBSERAVTIONS 
CHARECTERSTICS OF CASES INCLUDED IN THE STUDY 
 
 
TABLE -3 
CASE DISTRIBUTION 
GROUP No of cases Percentage of cases 
1 13 10.3 
2 25 19.8 
3 18 14.2 
4 17 13.5 
5 53 42.2 
Total 126 100 
 
 
126 patients were included in the study and they were divided into 
5 groups. Patients on D4T +3TC+NVP included in Group 1 (13), patients 
on D4T  +3TC + EVF  Group 2 (25)  , patients on ZDV+3TC +NVP  in 
Group 3 (18) , patients on ZDV+3TC+EVF in Group 4 (17) and  those 
patients not on HAART as Group 5 (53)  
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TABLE 4 
AGE DISTRIBUTION  OF THE POPULATION 
Age Group ( in years) 
20-29 30-39 40-49 Total 
Group 
No. % No. % No. % No. % 
 
Mea
n 
 
S.D. 
I 3 23.1 8 61.5 2 15.4 13 100 34 5.4 
II 4 16 13 52 8 32 25 100 36.6 6.1 
III 5 27.8 9 50 4 22.2 18 100 33.8 5.7 
IV 2 11.8 9 52.9 6 35.3 17 100 36.9 5.3 
Total 14 19.2 37 53.4 20 27.4 73 100 35.4 5.8 
‘p’ value for 
Groups I to IV 
0.2357 
Not Significant 
V 20 37.7 22 41.5 11 20.8 53 100 33.8 6.2 
‘p’ value for  
Group V 
0.1155 
Not significant 
 
19 % of the treatment group patients belonged to 20 -29 age group 
which is less compared to 37.7 % in the non treated group . 30- 39 age 
group accounted for maximum percentage of treatment groups( 53.4%)  
&  non treatment group (41.8%) of patients .40- 49 age group   accounted 
27.4% in treatment group 20.8%  non treated group. The p value is  not 
significant  among any of the groups. 
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TABLE- 5 
SEX DISTRIBUTION 
Treatment Groups  Group 5  
Sex No. % No. % 
Male 45 61.6 25 47.2 
Female 28 38.4 28 52.8 
Total 73 100 53 100 
‘p’ 0.152 
Not significant 
 
In the study  males were 61.6% in treatment group and 47.2% in 
non HAART Group and females accounted for 38.4 %in treatment group  
52.8 % in non HAART Group.  The p value is  not significant  
 
TABLE - 6 
MARITAL STATUS 
Marital status Group 1-4  No  Group1-4% No Group 5 No Group 5 % 
Married 64 87.6% 40 75.5% 
Unmarried 9 12.4% 13 24.5% 
Total 73 100% 53 100% 
In treatment groups  87. 6% and in non HAART treatment group 75.5% 
are married. 
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TABLE -7 
Study Group Control Group  
Parameter No. % No. % 
‘p’ = 0.3414 Not significant 
Smoking 
Non smoker 
Smoker 
Quit smoking 
 
31 
14 
8 
 
42.5 
19.2 
38.4 
 
27 
14 
12 
 
50.9 
26.4 
22.6 
‘p’ = 0.5583 Not significant 
Alcoholism 
Non alcoholic 
Alcoholic 
 
64 
9 
 
87.7 
12.3 
 
35 
18 
 
66 
34 
0.0069 Significant 
 
Non smokers,  smokers  and  people who quit  smoking in the 
HAART groups  are 42.5%,19% , 38.4% respectively . In non HAART 
treatment group 5 the percentage of  non smoker , smokers and people 
who quit smoking  are  50.9% , 26.4% and 22.6% respectively. 
 
Alcoholism in HAART group is 12.3% % against 34% in non HAART 
group. p value is 0.0069 and significant. 
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TABLE - 8 
OTHER PARAMETERS 
Study Group Control Group  
Parameter No. % No. % 
Hypertension 
Hypertensive 
Normotensive 
 
9 
64 
 
12.3 
87.7 
 
6 
47 
 
11.3 
88.7 
‘p’ = 0.9185 Not significant 
IFG/ IGT 
IFG present 
IGT present 
Normal 
 
2 
7 
64 
 
2.7 
9.6 
87.7 
 
2 
1 
50 
 
3.8 
1.9 
94.3 
‘p’ = 0.5583 Not significant 
IHD 
IHD Present 
No heart disease 
 
12 
61 
 
16.4 
83.6 
 
2 
51 
 
3.8 
96.2 
‘p’ = 0.051 Not significant 
 
Hypertension was present in 12.3% in study group compared to 
11.3% HAART Group .P value  not significant IFG was present in  2.7% 
study group while in non HAART group is 3.8 % p value not significant  
IGT  was  present in 9.6%  and 1.9%  HAART group and Non HAART 
group respectively. P value non significant. 
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                                             TABLE – 9 
 
Study Group Control Group  
Parameter No. % No. % 
IHD 
IHD Present 
No heart disease 
 
12 
61 
 
16.4 
83.6 
 
2 
51 
 
3.8 
96.2 
‘p’ = 0.051 Not significant 
 
IHD were present in 16% of  HAART group and 3.8% in non HAART 
group.  The  p value  is not  significant. 
 
TABLE - 10 
BMI 
 
HAART Group 
(I,II,III &IV) 
Non HAART Group
(V) 
BMI 
No. % No. % 
Underweight 27 37 14 26.4 
Healthy weight 44 60.3 39 73.6 
Overweight 2 2.7 - - 
Total 73 100 53 100 
Mean 
S.D. 
19.47 
1.96 
19.56 
1.8 
Mean value for BMI in  HAART groups  is 19.47 and 19.56 for Non 
HAART group The  p value is not significant(0.50). 
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                                             TABLE -11 
      MEAN CD- 4  COUNT OF HAART AND NON HAART GROUP 
CD 4 COUNT HAART GROUP NON HAART GROUP 
Mean 164.1 224.6 
SD 53 91 
 p            0.001  significant 
 
Mean CD-4 cell count among the HAART groups is 164.1 and in  
       Non HAART group is 224.6. The p value is significant. 
                                                      TABLE-12  
               CD- 4 CELL COUNT AMONG THE STUDY GROUPS 
HAART Group 
I,II,III,IV 
Non HAART 
Group V 
 CD4 CELL 
COUNT 
No. % No. % 
< 50       (A ) 6 8.2 5 9.4 
50-200   ( B) 43 58.9 14 26.4 
200-350  (C) 22 30.1 29      54.7 
>350       ( D)       2 2.8         5      9.4 
Total      73      100       53      100 
 
58.9% of the HAART group and 26.4% non HAART group belong to 50-
200 cell group while 30.1% in HAART and 54..7% in non HAART had 
CD -4 cell count in 200-350 range. 
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TABLE-13 
WAIST / HIP RATIO 
Treatment Group 
(I,II,III &IV) 
Untreated Group 
(V) 
Waist / Hip 
ratio 
No. % No. % 
Normal 12 16.4 19 35.8 
Abnormal 61 83.6 34 64.2 
Total 73 100 53 100 
Mean 
S.D. 
0.952 
0.068 
0.875 
0.06 
‘p’ 0.0001 
Significant 
 
Mean value for Waist / Hip ratio in HAART groups is .0952 and for non 
HAART groups is .0875 .The  p value is very significant. 
 
TABLE - 14 
BMI  AND WAIST / HIP ABNORMALITIES 
Normal Abnormal Parameter 
No. % No. % 
BMI 71 97.2 2 2.8 
Waist/Hip ratio 12 16.4 61 83.6 
‘p’ 0.0001 Significant 
 
Percentage of abnormal BMI in HAART groups was 2.8% and that of 
abnormal Waist/ hip ratio 83.6% .The  p value is  significant.  
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TABLE - 15  
 
LIPID  PROFILE IN STUDY GROUPS. I-IV 
 
  
I II III IV V  
Lipid Mean SD Mean SD Mean SD Mean SD Mean SD 
‘p’ value 
for 
Groups  
I to IV and 
Group V 
TC 196.3 26.2 244.5 32.9 178.2 15.7 220.2 23.6 168.5 30.8 0.0001 
Significant 
TGL 187.5 53.7 231.9 81.1 175.7 63.1 230.4 66 178 68 0.0403 
Significant 
LDL 121.6 23.1 168 23 102 11.1 138.4 21 93.9 26.4 0.0001 
Significant 
HDL 37 3.4 36.4 4.7 38.9 4.5 36.2 3 37.3 4.9 0.4189 
   Not 
Significant 
VLDL 37.5 11 45.5 17.1 35.1 12.6 45.9 13.3 35.6 13.6 0.0163 
Significant 
 
 
Mean values for Total Cholesterol in Group I is 196 mg% ,Group 
II is 244.5 mg%, Group III is 178.2 mg % , group IV is  220.2 % and 
Group V is 168.5 %. P value for group  I-IV HAART groups to Group V 
is significant.  
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The mean values for LDL for Group I is121 mg%    , Group II is 
168 mg%  , Group III  is  102 mg% Group  IV is  138.4 mg %  and Group 
V 93.9 mg% .The   p value of HAART Groups to Group V not on 
HAART is significant. 
Serum Triglycerides   mean values for Group I , Group II ,Group 
III, Group IV   and Group V are 187.5 mg% , 231.9mg % , 175.7mg%,  
230.7mg%  178 mg%   respectively .The   p value of Group 1-IV  to 
Group V is (0.040)  is   significant.   
Serum HDL mean values for group I  group II ,group III ,group IV  
and group V are 37 mg% , 36.4mg%, 38.9mg % ,36.2  mg%  and 37.3 
mg%  respectively. p value is not significant. The mean values for mean 
VLDL  values in Groups I to V are 37.5mg%, 45.5mg% ,35.1 mg% ,45.9  
mg%  and 35.6  mg% . The  p value is significant (0 .016)  
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                DISCUSSION & COMPARATIVE ANALYSIS 
The global pandemic HIV infection & AIDS  is virtually reported  
from all countries with a global prevalence of 33.2 million  and incidence 
of 2.5 million  new cases every year2. After the introduction of    HAART  
(Highly Active Anti Retroviral Therapy) & effective control of 
opportunistic infections patients with  HIV infection and AIDS are  
surviving a longer period of  life 5. As a result of this chronic 
complications of HIV infection and HAART is being recognized  more 
.Metabolic body fat abnormalities are increasing in HIV population 
especially in patients on HAART 6,10,35.These include dyslipidemia, 
lipoatrophy, IFG ,IGT and abdominal obesity which are known risk 
factors for cardiovascular disease10 . This study aims in comparing the 
dyslipidemia in HIV patients on HAART to HIV patients not on HAART.  
HIV prevalence in India according to HIV Sentinel Surveillance in 
2007  by NACO estimated a prevalence of 2.31 million of PLAH  ( 
People Living With HIV and AIDS )in India.3 Females constitute around 
39% of the burden (0.9 million).3 Children below 15 years constitute 
3.5% of the estimated number of PLHA while elderly people with age 
greater than 49 years constitute 7.8%. Adults aged 15-49 years constitute 
88.7% of the estimated number of PLHA 
The study was conducted in adult patients attending ART centre 
and Department of  Internal  Medicine Madurai Medical College. In this 
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study the age group selected was from 20-49 which is the most common 
age group affected by the disease and for the purpose  that lipid 
abnormalities are more common in these age group.3,94  
Age distribution showed maximum prevalence in the 30 -39 age  
group among  HAART groups I-IV( 52%) and non HAART group V 
(48%).There was no statistically significant  difference in age distribution 
among the groups. 2,3 
There was no significant difference in the sex distribution among 
the population. Sex distribution in  this study showed 61.6% males 38.4 
% females  in study group 1-IV and in group V  is 47.2% and 52 .8% . 
There was no statistically significant difference in sex distribution but 
study Groups showed values similar to those in  HIV Sentinel 
surveillance  2007 done by NACO3 and UNAIDS report 20082. 
In this study active smokers were  19.2 % in HAART groups  and 
26.4 %.    in GROUP V. Those who quit smoking was high among the 
HAART group (38%) compared to the non HAART group (12%) . Most 
of the non smokers are women  87.5% in HAART groups and 92.5 % in 
non HAART group.  In the  HAART groups 62.2% of the males where 
smoker who quit smoking compared to 42 % in the non HAART group. 
There was no statistically significant difference in the smoking pattern.  
National sample survey showed 61.3% of tobacco users in rural & 40.7 % 
in urban areas in India97 
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In this study 97 % of the males are smokers with 62.2 % quit 
smoking. This high prevalence may be attributed to the high risk behavior 
of these  patients. 
Prevalence of  alcoholism in HAART group is 12.3 against 34% in 
non HAART. Alcoholics with abnormal liver functions were excluded 
from study This difference in the prevalence is due to counseling for ART 
therapy which helped the patients to quit alcohol. p value comparing the 
HAART group and the non HAART group is significant 0.069. 
According to the study of Nuefeld KJ  etaland  National sample survey 
1993-95 showed a prevalence of Alcohol use in 4.5 % of the population 
which is lesser than those on HAART treatment  12.3% and 34 % in non 
HAART group. All the females were non alcoholics .4 
The patients of both groups were divided on basis of CD-4 counts 
as A ,B,C,D groups with  counts <50,50-200,200-350 and >350 cell/mm3 
respectively. The  prevalence of very low CD -4 count is 8.2% and 9.4% 
in the HAART group and non HAART group respectively.58.9%  of 
HAART group and 26.4% non HAART patients  were in group B while 
30% of HAART group and 54% non non HAART group belonged to 
category C.Mean p value for non HAART group(224/mm3) was higher 
than HAART group (164 /mm3) .The p value was significant between the 
HAART and non HAART groups. There was no significant difference in  
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in CD-4 cell count distribution among the  treatment groups and no 
significant relation was found with lipid alterations in this study. 
   In this study prevalence of hypertension was  12.3 % in HAART groups 
and 11.2 % in non HAART group. Study from urban Chennai, Mohan et 
al
62 
reported 8.4% prevalence of hypertension among men and women 
aged 20 years and above and belonging to the low socio economic group 
(based on household income, occupation and dietary pattern). Similarly, 
in the middle socio economic group had a higher prevalence (15%) 
conducted in 1996-97 .There is  increased  prevalence noticed in   the 
group IV  (17.5%) group I  (15% ) but not statistically significant. 
In 2000, Ramchandran A  Snehalatha C et al  Diabetes 
Epidemiology Study Group of India( DESI study)  a multi centric study
101    
involving six urban cities in India (Chennai, Bangalore, Hyderabad, 
Mumbai, Culcutta and New Delhi) among the age groups of 20 and above 
showed a prevalence of 14% among men and women (sample size: 5288 
men; 5928 women). 
 In this study six   patients were excluded from study according to 
exclusion criteria. 2 patients( 2.7%) in HAART  groups was detected to 
have  IFG and  7 (9.6%) patients had IGT  compared to 2 cases of IFG( 
3.8%)  and 1 case of IGT( 1.9%)  in non HAART group. This was  not 
statistically  significant . Carr et al.  reported a 7% incidence of new-
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onset diabetes among HIV patients  as diagnosed by a two-hour blood 
glucose value>200mg/dl after administration of an oral glucose tolerance 
test .10 IGT  and IFG which are forerunners  of diabetes, were found in 
12.3% in the study group  after excluding diabetes cases from the study as  
against 12 % in urban Chennai population 10 and  13.2% in South Asian 
population according to International Diabetes Federation.  
Abnormalities in body composition have been reported in 40 to 50 
percent of ambulatory HIV-infected patients, according  to  Lichtenstein 
KA, Ward DJ  et al.11,12 The proportion is greater in those receiving 
combination antiretroviral therapy.11 The physical appearance of  
lipodystrophy is more apparent usually by 2 years of HAART therapy 6,12. 
With the increase of life expectancy  ,HIV patients treated with HAART 
reaching up to 49.5 years   when treatment is started at  the age of 20 
years11.  Prevalence rates of lipodystrophy  vary widely, from 11 to 83 
percent, in cross-sectional studies.10, Anthropometric parameters are 
important tools for measurement of lipodystrophy including weight ,BMI, 
Waist / Hip ratio, skin fold thickness6. 
Many of the studies failed to show good correlation with 
lipoatrophy and  anthropometry 6 .  Jean-Guy Baril, Patrice Junod, Roger 
LeBlanc et al in their study found a weak correlation with lipodystrophy 
and  Waist / Hip ratio in  HIV patients on indinavir  and stavudine.28 
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In this study 30.4% of the  HAART group and 26.4% of the non 
HAART group were underweight and 62 % in  HAART  and  68%  in 
non HAART  had a normal BMI..2.7% in HAART  group and 5.6% in 
non HAART group are overweight but have no statistical significance. 
Lichtenstein KA, Ward DJ et al in their study concluded that a decreasing 
BMI rather  than  increasing  BMI  ,increased Triglycerides , older age 
and female sex are more prone for lipodystrophy.10 
Mean BMI values for the study in all the groups were between 
19.5-19.9. P value was not significant among the HAART groups and 
also relating to the non HAART treatment groups. 
Waist Hip ratio  value analysis showed   a mean value in the 
HAART group  between 0.932-0.96 which is above the guideline values 
for men(> 0.90) as well as women(>0.80). The  mean Waist / Hip  ratio 
for the non HAART group was found to be  0.875  in which 64% had an 
abnormal values. There was no statistically significant difference among 
the treatment groups but significant in comparison to   non HAART 
group. The p value  for the treatment groups to non HAART group was 
significant.(p- 0.001). 
This shows  Waist /Hip has significant relation to long standing 
illness and abdominal obesity. There was an increase in Waist / Hip ratio 
by 0.07 between the HAART groups and non HAART groups which is 
statistically significant.102 
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Considering the anthropometric measurements observation in this 
study is that Waist /Hip ratio is a better parameter for assessing the 
visceral adiposity. Low BMI   reflects the weight loss in with progression 
of disease and an increasing Waist Hip ratio denoting the visceral 
adiposity. The   p (0.001) value is statistically significant. 
The DAD Study Group ( Data  Collection on Adverse Events of 
Anti-HIV Drugs)  by Jens Lundgren and et al  in Copenhagen  have done 
extensive studies in the growing metabolic complications in HIV from 
1999.  They have demonstrated a definite association between 
combination antiretroviral therapy and the dyslipidemia   and 
cardiovascular risk. Its is an International collaboration study including 
investigators from all parts of the world in an HIV patient cohort of 
24,437. During the first phase of study they demonstrated  increased 
dyslipidemias  and cardiovascular risk is increased in HIV patients   
especially with PI and NNRTI based HAART on a 4 year follow up. 
The second phase they proved an  increased  incidence of  (345 deaths )  
cardiac events including myocardial infarction in the 94,469 patients 
years  Incidence of cardiac events was 3.65 /1000 population . The 
incidence of myocardial infarction increased from 1.53 per 1000 person-
years in those not exposed to protease inhibitors to 6.01 per 1000 person-
years in those exposed to protease inhibitors for more than 6 years. After 
adjustment for exposure to the other drug class and established 
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cardiovascular risk factors (excluding lipid levels), the relative rate of 
myocardial infarction per year of protease-inhibitor exposure was 1.16, 
whereas the relative rate per year of exposure to non nucleoside reverse-
transcriptase inhibitors was 1.05 . 10,95,96 
E Frontas , Friis Moller et al in their study  ( DAD study first phase) 
found that  dyslipidemia occurred in patients among all  HAART  groups 
including Protease inhibitor , NNRTI  as well as NRTI. Patients on 
Protease inhibitor especially dual protease inhibitor had more lipid 
abnormalities. 
The mean values for patients on Single PI therapy ,total cholesterol 
was 204 mg%, LDL 139.2 mg %, HDL 38 mg% and TG 159 mg% .In 
patients treated with double PI regime the  mean values were 220mg%, 
148mg%, 38 mg% and 221 mg% respectively. 
In NNRTI based regimens the means values were TC  197 mg%, 
LDL 123 mg% ,HDL 40 mg% and TGL 115 mg% . 
In our study none of the patients received PI based regimes but  all 
the 73 patients in  study Group I-IV  were on 2NRTI  + 1 NNRTI based 
regimes. The mean value of  total cholesterol is 213 .9 mg% in HAART 
treatment group( 1-4)  compared to 168.5 in the non HAART group (5) . 
The p value is significant 0.001 . 
The mean LDL values are 136.6 mg % and 93.9 mg% among 
respective groups. The mean TGL  and HDL values  are  209 mg % ,178 
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mg %  and 37.1 mg% and 37.3 mg% among the HAART and non 
HAART groups respectively. Except  for HDL all the lipid parameters 
showed statistical significance when  the HAART  groups were  
compared to  non HAART group .In the DAD  study group values of 
mean  total cholesterol and LDL were less compared to this study but  
showed similar elevation. This may be attributed to the difference in the 
study population as DAD study was  conducted  in European  and North 
American population while this study is in Asian population who are 
inherently prone for Metabolic syndrome & dyslipidemias.70,95,96 
In DAD  study the percentage of total cholesterol  elevated above 
240 mg%  i.e. (high level ) was  23 % among HAART group  and 8 %  
untreated patients . In this study values of TC  above 240 mg% are 24.7% 
and 5.7% .The TGL was elevation in DAD study group is  32 % and 15% 
in HAART & untreated group respectively.10  In this study the TGL 
elevations are 45 % and 30 % respectively. This increased value may be 
due to combined effect of NNRTI + NRTI  as well as the difference in the 
population as  South Asians populations are more   prone for Metabolic 
syndrome and hypertriglyceridemia. HDL less than 35 mg% was seen in 
25% of both groups in DAD study while it was seen in 29 % in this study 
in HAART treatment group and 21 % in non treatment group. 
Margaret May, Jonathan A C Sterne, Martin Shipley, Eric Brunne  
et al in their study  of 13300 HIV infected  men  who are  aged 40-70 
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were  divided into  two groups  parametric model based on the Gompertz 
distribution generalized best. Variables included in the model were 
systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, triglyceride, glucose, diabetes mellitus, body mass index and 
smoking status. Compared with patients not on HAART, the estimated 
CHD hazard ratio (HR) for patients on HAART was 1.46  for moderate 
and 2.48  for severe metabolic complications. The  study also showed that 
the   hazard  ratio for those with severe lipid abnormalities  was more 
(2.46)  than in smokers (2 .0). 
 Analysis of the data in this  study showed that all the lipid parameters  
abnormalities where more pronounced in the group which had nevirapine 
and stavudine  compared to efavirenz and zidovudine based     regimes. 
The Group II followed by Group IV Group I and Group III had   
decreasing order of lipid abnormalities which was noticed in the      study. 
 
The mean total cholesterol was 244.5 mg% , 222mg%.196 mg% 
178 mg% in the Group I, Group IV  Group I and Group III respectively. 
The  p value  is significant .Similarly there was statistically significant 
increase in LDL , TGL and VLDL.  There was also a decrease in HDL 
which was not statistically significant. 
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The percentage of patients with elevated total cholesterol, 
triglycerides and decreased high-density lipoprotein (HDL) cholesterol is 
shown by the class of antiretroviral drugs (ARVs) . Data  are from (DAD) 
Study Group in 2003. 
 
Randomized control study  for a period  of  three years in 600 HIV 
patients  with two different regimes was done by Joel E. Gallant, 
Schlomo Staszewski et al . The results of the study showed that 
Tenofovir+ Efavirenz+ Lamuvidine regime  compared to Stavudine + 
Lamuvidine+ Efavirenz regime  was equally  effective in reducing viral 
load with significantly less lipid alterations.  
. 
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Stephen J Kerr  ,Chris Duncombe et al in their study reported 
dyslipidemia in  Asian  HIV patients  after treatment for two years  in 
Thailand. The study was done in treatment naïve HIV  population who 
were started on  Protease Inhibitor-containing regimen , stavudine based 
NNRTI regimen and  zidovudine based regimes . Results of the study 
showed   that PI   based regimen had  more lipid abnormalities than non 
Stauvidne based NRTI  + NNRTI regimes94.  
Leonardo Calza; Roberto Manfredi;   et al studied the difference of 
lipid abnormalities in HIV patients  on PI based regimens with two  
different NNRTI-  efavirenz and nevirapine .The study was done in 
treatment naïve 696 HIV patients  .  107 patients  where selected form the 
total population  who had mixed dyslipidemias following PI therapy after 
6 months . They were randomized  and was followed up for 6 months.95,96 
The study included 4 arms  A- nevirapine arm B efavirenz arm C- 
pravastatin arm and D- Bebzofibrate arm . 
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The result of the study showed patients on nevirapine  arm did well 
in both  Triglyceride arm Total cholesterol  causing a lowering  of both 
parameters by 23% and 29 %. while in efavirenz based arm the results 
was 9 % and 11% reduction  after switching from PI based regimes.94,95 
Similar observation  in our study is that   lipid  profiles in Group I 
(nevirapine containing) compared  to Group II ((efavirenz based) 
regimen. In this study the  total cholesterol levels in GroupII is 244 mg% 
and 196 mg% in Group I; similarly Triglycerides  are 231 mg% and 181 
mg% in the respective groups.The p value is statistically  very significant. 
Similar results was obtained  in lipid  levels comparing  Group  III   ( 
nevirapine based  )  to    Group    IV ( efavirenz based  ) . Total  
cholesterol is 220 mg% in Group IV and 178 mg% in Group III while 
triglycerides values are  230 mg% and 175 mg% respectively. 
This results clearly shows a more abnormal lipid profiles in 
efavirenz based regmies than nevirapine containing regimes.  Nevirapine 
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is a better drug   substitution for  PI  in patients with multiple risk factor 
for cardiovascular event94,95. The study also shows that non stavudine  
based regimes have more lipid abnormalities than  zidovudine based 
regimes 103. In this study the Group I ( stavudine based ) has more lipid 
abnormalities compared to Group III ( zidovudine based). 
Atherogenic Index of the plasma is the ratio of total triglycerides 
and HDL and a value below 5 is desirable. In our study  the Atherogenic 
Index was 6.37 for Group II &IV , 5.05 for Group I , 4.5 for Group III   
and 4.7 for  Group V. Mean  value among the HAART group is 5.57 and 
is statistically significant to non HAART population with  p value 
0.002.95 ,96  
Total Cholesterol to HDL ratio in this study  is 5.29 in Group I, 6.7 
in Group II  ,4.54 in Group III, 6.07 in Group IV and 4.5 in Group V. In 
the DAD study  the mean values TC:HDL ratio was 3.9 in  treatment 
naïve group and 5.3 in  HAART treatment Group.96  This shows the 
increased Atherosclerotic and cardiovascular risk in these population. 
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CONCLUSION 
1. Significant Metabolic and morphological alterations occur in HIV  
infected patients especially in patients  on Highly Active Anti-
retroviral  Therapy. 
 
2. There is a statistically significant increase in the total cholesterol, 
Triglycerides LDL cholesterol .There is statistically insignificant 
decrease in HDL cholesterol in HIV patients on HAART . 
 
3. There is an increased   prevalence  of hypertension and IGT in the 
HIV    patients on  HAART .There is an increase in the prevalence 
of IHD in the treatment groups compared to non HAART group. 
 
4. Increasing BMI  is a poor indicator of visceral adiposity and 
dyslipidemia in HIV patients on the contrary it decrease with 
increasing dyslipidemia. Waist Hip ratio shows significant 
correlation with  visceral adiposity and dyslipidemia. 
 
5. Dyslipidemia is more in the efavirenz based as well as stavudine    
containing  regimes compared to nevirapine and zidovudine 
containing regimes . 
 
6. The study doesn’t   include PI based regimes which has more 
impact on   metabolic parameters. 
 
7. Base line Anthropometric and metabolic assessment including lipid 
profile, fasting blood sugar should be done as initial workup in 
every  newly  detected seroconverters as well as in patients  
planned for HAART therapy.                        
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                                             SUMMARY 
This prevalence study was conducted in the background that dyslipidemia 
and cardiovascular mortality is reported to increase in HIV patients 
especially on Anti-retroviral therapy. In this study 126   patients who 
were attending the Antiretroviral therapy centre GRH Madurai & 
Medicine wards were included and divided into five different groups 
according to the anti retroviral therapy after obtaining   Ethical 
Committee clearance from  the institution .Patients with HIV infection 
were initiated on Anti-retroviral  therapy based on WHO guidelines. 
Patients who were exposed to HAART for   more than 2 years were 
selected in the treatment group and compared to age and sex   matched 
treatment naïve group. Biochemical and anthropometric analysis were 
done and results entered in master chart which was statistically analyzed  
using computer and EPI 2002 software. 
The results of the study showed an increased prevalence of disease 
among  the 30-39  age group with increased prevalence a among males  in 
the  HAART groups. The Anthropometric parameters  on analysis 
showed a mean BMI of both HAART and treatment naive Groups in the 
low normal range. Waist Hip ratio revealed  mean of 0.952 HAART 
groups and 0.875 in treatment naïve  group. This showed a significant 
correlation to Waist hip ratio and the disease while fall in BMI  was seen 
rather than an  increase in BMI . 
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The lipid analysis   showed a significant increase in the total 
cholesterol, LDL and VLDL in both the HAART groups and treatment 
naïve groups. There was an insignificant fall in HDL levels in both 
groups. The abnormalities in lipid were more in HAART group  
especially the stavudine and efavirenz based regimes. When both  drugs 
were  present together as in Group II,  patients had the maximum 
alteration in lipid levels.  
The Group II followed by Group IV Group I and Group III  are in 
decreasing order of lipid abnormalities noticed in the study. The mean 
total cholesterol was 244.5 mg% , 222mg%.196 mg% 178 mg% in the 
Group II, Group IV ,Group I and Group III respectively p value  is 
significant .Similarly there was statistically significant increase in LDL , 
TGL and VLDL. 
On basis of many studies now PI are now reserved  for failure of 
primary regimen .Patients on PI developing metabolic derangements   
nevirapine is a better substitute  than efavirenz. Similarly  studies have 
show proven benefit by switching  stavudine with tenofovir and abacavir 
with equally good  viral suppression and less dyslipidemia.101 
The strategies like screening and  monitoring the lipid every 6 
months , switching to lipid friendly drugs , lipid modifying drugs as well 
as change in life style may help to nullify the increased cardiovascular 
risk and mortality in HIV patients.96 
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GLOSSARY 
   
1. HIV – Human Immuno deficiency Virus  
2. AIDS- Acquired Immuno deficency Syndrome  
3. HAART- Highly Active Anti Retroviral Therapy 
4. ART- Anti Retroviral Therapy 
5. NRTI- Nucleoside Reverse transcriptase inhibitor 
6. NNRTI-Non Nucleoside Reverse transcriptase inhibitor 
7. PI-Protease Inhibitor  
8. PLHA-People Living with HIV and AIDS 
9. NACO- National AIDS Control Organisation 
10. D4T- Stavudine 
11. 3TC- Lamuvidine  
12. CAD – Coronary Artery Disease 
13. INF- α- Interferon  Alpha  
14. TNF α- Tumor Necrosis Factor Alpha  
15. SREBPI- Sterol Regulatory Enhancer-Binding Protein-1(SREBPI) 
16. PLAH – People Living with HIV and AIDS 
17. PPARγ- Peroxisome Proliferatory Receptor   Gamma. 
18. STD -Sexually Transmitted Diseases 
 
 
                                                                                  PROFORMA 
Dyslipidemia in HIV patients on HAART and Treatment naïve  
HIV patients 
Name                               Age                      Sex 
IP No:                              Occupation 
Marital status                   WHO stage 
Educational status 
Clinical status 
H/o  IHD  
        Diabeties 
        CVA  
        Hypertension  
        POVD 
 
Personal History  
 
Smoking ; Y/N   Duration         Packs/Day 
Alcohol  :Y/N     Duration 
Diet       : Veg / Non veg 
Family  History  
   Diabeties  : Y/N 
   IHD          : Y/N 
Examination 
 Height               Weight                  BMI 
  WC                   HC                      WC/HC 
   Pulse Rate        BP                       Respiratory rate 
Systems 
 
 
 Cardiovascular  
 Respiratory 
 Nuerological status 
 GIT 
  
 
 
 Treatment Groups  
1. Lamuvidine/Staudine/Nevirapine 
2. Lamuvidine/Stuvidine / Efavirenz 
3. Lamuvidine/ Zidovudine/ Nevirapine 
4. Lamivudine/Zidovudine/Efavirenz 
5.  HAART naïve patients  
 
 
 
Investigations 
 
1 Urine   Albumin                  2 Spot PCR  
               Sugar  
               Deposits 
3 Fasting blood sugar            4   2hr Postprandial 
 
5 Blood Urea                 Serum Creatinine 
 
6 Lipid Profile                           
 
 Total Cholesterol                        
 Triglycerides                               
 HDL 
 VLDL 
  LDL 
 
7  LFT 
 
8 CD 4 Count 
  
9. ECG 
MASTER CHART 
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1 F 5 35 18 0.9 2 148 210 71 32 44 3 0 2 0 230 
2 F 5 33 17.5 0.85 2 169 125 100 42 25 3 0 2 0 212 
3 F 5 29 19 0.83 2 172 139 104 40 28 3 0 2 0 450 
4 F 5 42 24 0.8 2 168 270 77 41 54 3 0 2 0 85 
5 M 5 35 18.5 0.78 2 186 235 106 21 47 3 1 2 0 175 
6 F 5 35 19 0.81 2 154 185 78 35 37 3 0 2 0 294 
7 M 5 28 19 0.93 2 166 143 96 41 29 3 2 2 1 330 
8 M 5 39 22 0.94 1 160 219 80 36 44 3 2 2 0 38 
9 F 5 25 20 0.88 2 165 142 100 32 28 3 0 2 0 402 
10 M 5 42 18 0.87 2 193 285 105 31 57 1 1 1 1 232 
11 M 5 33 19 0.86 2 177 173 99 41 35 3 1 2 1 256 
12 M 5 37 22 0.98 2 181 142 118 30 28 3 2 2 0 330 
13 M 5 25 21 0.91 2 156 138 72 42 28 3 2 2 0 177 
14 F 5 29 19 0.93 2 152 163 78 43 33 3 0 2 0 156 
15 F 5 44 20 0.91 2 189 148 109 41 30 3 0 2 0 267 
16 M 5 26 23 0.94 1 225 331 127 32 65 3 0 2 1 21 
17 F 5 28 21 0.81 2 171 139 99 42 28 3 2 2 0 332 
18 F 5 29 19 0.82 2 146 187 69 40 36 3 0 2 0 238 
19 F 5 31 22 0.78 2 138 147 68 41 30 3 0 2 0 145 
20 M 5 37 20 0.92 2 200 278 110 30 56 3 0 2 0 247 
21 M 5 44 17 0.97 2 165 302 67 34 60 3 2 2 1 209 
22 M 5 33 19 0.87 2 169 119 103 41 24 3 2 2 1 265 
23 M 5 39 16 0.82 2 129 86 72 40 17 3 1 2 1 198 
24 M 5 28 17 0.86 2 152 113 88 41 22 3 1 2 0 245 
25 F 5 36 21 0.91 2 153 230 73 34 46 3 0 2 0 268 
26 F 5 25 20 0.93 2 152 108 88 42 22 3 0 2 0 275 
27 F 5 29 18 0.81 2 159 132 95 35 26 3 0 2 0 91 
28 M 5 27 18 0.91 2 149 109 87 40 21 3 1 2 1 241 
29 F 5 39 19.5 0.84 2 160 186 85 32 35 3 0 2 0 245 
30 M 5 42 21 0.9 1 242 385 133 32 77 1 2 2 1 40 
31 M 5 40 16 0.88 2 231 275 141 30 55 3 2 2 1 256 
32 F 5 41 18 0.79 2 176 149 106 40 30 3 0 2 0 132 
33 M 5 45 20 0.99 2 173 188 101 31 38 3 1 2 0 85 
34 F 5 39 21 0.86 2 149 126 78 42 25 3 1 2 0 288 
35 F 5 40 18 0.85 1 167 317 70 34 63 3 1 2 0 298 
36 M 5 36 19 0.86 2 160 138 93 39 28 3 1 2 1 47 
37 M 5 28 19 0.76 2 177 98 110 47 20 3 2 2 1 188 
38 M 5 29 18 0.97 2 134 129 70 38 26 3 1 2 1 311 
39 F 5 28 17 0.84 2 169 193 95 35 39 3 0 2 0 404 
40 F 5 24 19 0.81 2 109 122 44 41 24 3 0 2 0 120 
41 F 5 38 21 0.91 1 246 200 171 35 40 2 0 2 0 221 
42 F 5 25 21 0.8 2 116 121 50 41 24 3 0 2 0 293 
43 M 5 26 21 0.85 2 155 141 87 40 28 3 2 2 1 357 
44 F 5 27 23 0.9 2 114 172 42 38 34 3 2 2 0 217 
45 F 5 32 22 0.91 2 208 175 139 34 35 3 0 2 0 125 
46 M 5 41 19 0.85 1 253 229 172 35 46 3 1 2 1 285 
47 M 5 43 18 0.96 2 170 245 81 40 49 3 1 1 1 165 
48 F 5 35 19 0.88 2 159 128 88 46 26 3 0 2 0 35 
49 F 5 36 21 0.83 2 123 85 66 38 17 3 0 2 0 244 
50 F 5 37 20 0.79 2 168 96 108 40 19 3 0 2 0 234 
51 M 5 38 20 0.89 2 177 189 104 35 38 3 0 2 1 355 
52 M 5 32 19 0.89 2 190 210 109 39 42 3 1 2 1 123 
53 F 5 25 21 1.01 2 160 138 95 37 28 3 0 2 0 267 
54 F 4 3O 18 0.89 2 240 185 165 38 37 3 0 2 0 302 
55 F 1 43 19 0.99 2 223 236 142 34 47 3 0 2 0 227 
56 M 2 44 17 1.04 1 270 247 189 32 49 3 2 1 0 367 
57 M 3 28 21 0.9 2 175 139 106 41 28 3 1 2 0 225 
58 M 3 37 20 1.1 2 186 167 112 41 33 2 0 2 0 210 
59 M 1 35 17 0.96 2 176 199 104 32 40 3 2 2 0 145 
60 F 4 38 15 0.96 2 289 255 199 39 51 3 0 2 0 97 
61 M 2 42 18 0.96 2 256 200 179 37 40 3 2 1 0 108 
62 F 3 41 19 0.95 2 192 317 95 34 63 1 0 2 0 105 
63 F 2 39 17 0.96 2 231 178 183 33 26 3 0 2 0 54 
64 M 3 33 20 0.88 2 185 147 101 37 29 3 1 2 0 43 
65 F 3 30 21 0.92 2 183 127 111 39 25 3 1 2 0 165 
66 M 2 28 26 0.88 2 276 321   176 36 64 3 2 2 1 
383 
67 M 4 32 20 0.89 2 198 143 131 38 28 3 2 2 1 165 
68 F 3 39 18 0.93 2 154 184 79 38 37 3 0 2 0 208 
69 F 1 39 19 1.03 2 209 147 139 41 30 3 0 1 0 245 
70 M 3 40 18 0.98 2 217 277 127 35 56 3 2 2 1 166 
71 M 2 42 22 1.04 1 239 178 170 35 35 3 2 2 0 208 
72 M 2 29 19 0.96 2 270 365 165 32 73 3 2 2 0 76 
73 M 4 33 18 0.94 2 206 237 126 33 47 3 1 2 1 103 
74 F 2 41 19 0.89 2 277 409 162 33 82 3 0 2 0 65 
75 F 3 32 18 0.93 2 174 127 101 48 25 3 0 2 0 111 
76 M 2 36 19 0.94 2 276 142 214 33 28 2 0 2 0 208 
77 F 4 39 20 1.1 1 227 291 129 33 58 3 0 1 1 221 
78 M 3 29 17 0.88 2 179 147 103 47 29 3 1 2 0 109 
79 M 2 22 18 1.06 2 287 307 190 35 62 3 1 2 0 105 
80 F 1 37 20 0.98 2 238 146 168 41 29 3 0 2 0 49 
81 F 4 36 18 1.01 1 215 285 134 39 57 3 0 2 0 77 
82 M 1 28 18 0.99 2 204 257 116 36 52 3 2 2 0 83 
83 M 4 44 19 0.9 2 230 233 150 34 47 3 2 2 0 45 
84 F 4 44 18 0.89 1 222 285 132 33 57 3 0 1 0 39 
85 F 3 39 20 0.86 2 169 139 99 42 28 3 0 2 0 152 
86 M 3 42 21 0.95 2 195 241 112 35 48 3 1 2 0 109 
87 M 1 26 22 1.06 2 166 179 91 39 36 3 1 2 0 217 
88 M 2 38 21 0.92 2 154 187 141 48 25 3 0 2 0 235 
89 F 3 36 17 0.94 2 189 239 110 32 48 3 0 2 0 208 
90 F 1 30 19 0.88 2 195 176 124 35 35 3 0 2 0 214 
91 M 4 29 20 0.93 2 217 129 150 42 26 3 2 2 0 231 
92 M 2 32 23 0.96 2 295 176 225 35 35 2 2 2 0 188 
93 F 2 32 21 0.95 2 262 288 171 33 58 3 0 2 0 197 
94 M 3 24 21 0.96 2 186 247 94 34 49 1 2 1 0 201 
95 M 2 43 20 0.95 2 228 157 152 45 32 3 2 2 0 223 
96 M 4 36 18 0.98 2 218 211 138 37 42 3 2 2 1 95 
97 F 4 29 19 0.97 2 200 239 119 33 48 3 0 2 0 46 
98 M 3 33 18 0.88 1 172 119 106 42 24 3 2 2 0 104 
99 M 4 41 21 1.09 2 214 267 126 34 53 3 2 2 0 138 
100 M 2 37 24 0.89 2 245 365 131 31 73 2 2 1 0 179 
101 M 1 31 18 0.89 2 178 147 106 42 28 3 1 2 0 188 
102 M 2 22 21 1.07 2 265 189 190 37 38 2 1 1 1 195 
103 M 1 42 21 1.03 1 177 169 107 36 34 3 1 2 0 266 
104 M 2 38 18 0.91 2 198 241 167 34 48 3 2 2 0 200 
105 F 4 36 17 0.8 2 178 163 105 40 33 3 0 1 0 179 
106 F 2 40 20 0.91 2 199 124 129 45 25 3 0 2 0 175 
107 M 2 31 20 0.96 2 238 222 156 38 44 3 2 2 0 44 
108 M 1 35 21 0.94 2 205 169 136 33 34 3 2 2 1 65 
109 F 1 31 26 0.89 1 241 313 144 34 63 2 0 2 0 117 
110 M 2 37 20 1.06 2 254 266 166 35 53 3 1 2 0 368 
111 F 3 25 19 0.96 2 169 98 106 43 20 3 0 1 0 135 
112 F 4 38 19 1.01 2 206 183 134 36 35 3 0 2 0 199 
113 M 2 36 18 1.05 2 257 276 168 34 55 3 2 2 1 265 
114 M 4 44 21 0.96 2 239 298 144 35 59 3 2 2 0 177 
115 M 4 42 21 0.99 2 229 368 123 33 74 3 2 2 0 109 
116 F 2 39 18 0.86 2 241 206 171 39 41 3 0 2 0 169 
117 M 2 43 17 0.84 2 205 122 146 45 24 3 0 2 0 188 
118 F 3 33 19 0.88 2 170 196 96 35 39 3 0 2 0 178 
119 F 3 27 18 0.92 2 160 138 94 37 28 2 0 2 0 249 
120 M 1 36 18 0.94 2 163 187 90 37 37 3 2 2 0 199 
121 M 2 36 19 1.07 2 254 317 159 32 64 3 2 2 0 167 
122 M 3 40 21 0.96 2 152 114 84 41 23 3 2 1 0 77 
123 M 2 42 21 0.96 2 227 139 160 39 28 3 2 1 0 139 
124 M 2 37 18 1.04 1 208 175 139 34 35 3 1 2 0 266 
125 M 1 29 21 0.9 2 177 112 114 41 22 3 1 2 0 145 
126 F 4 30 20 0.81 2 216 145 148 39 29 3 0 2 0 97 
KEYS TO MASTER CHART 
  
Variables 
 SEX  
       M- Male  
       F – Female  
 S- Smoking 
     0-non smoker 
      1-smoker 
      2-quit smoking 
BMI- Body mass index 
W/H –  Waist Hip ratio 
HTN- 
1- Hypertensive 
2- Normotensive 
 
IFG/IGT – Impaired Fasting Glucose / Impaired Glucose Tolerance  
       1-  IFG  Detected  
       2- IGT  Detected  
       3 - No IFG and IGT  
       
 
G-Group 
1 -D4T+3TC+NVP 
2 -D4T+3TC+EVF 
3 -ZVD+3TC+NVP  
4 -ZVD+3TC+ EVF 
5 -HIV  not on ART 
A- ALOCHOLIC  
0- NON ALCOHOLIC  
     1-ALOCHOLIC  
IHD-Ischemic heart disease. 
1- no heart disease 
2- present 
TC.-Total cholesterol 
TGL- Triglycerides  
LDL-Low density lipoprotein 
VLDL-very low density lipoprotein 
 
 
 
 
 
 
 
 
                                  
 
 
                     
 
 
 
 
PREVALENCE OF HIV IN DIFFERENT   GROUPS IN   INDIA 
 
Fig 2 
 
 
 
 
 
ANC- Antenatal Clinics STD – Sexually Transmitted Disease Clinics 
IDU – Injectable Drug Abusers .MSM- Male Sex with Male 
FSW- Female Sex Workers. Prevalence in percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    MECHANISM OF DYLIPDIEMIA IN HIV  PATIENTS  AND 
HAART  
 
      Fig 3 
 
 
 
 
 
 
DISTRIBUTION OF  MEAN AGE  AMONG STUDY 
GROUPS I-IV 
 
 
 
 
 
 
 
Fig-4 
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                                WAIST/ HIP RATIO  AND BMI 
 
 
 
 
 
Fig -6 
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MEAN LIPID VALUES OF THE STUDY GROUPS. I-V 
 
 
 
Fig- 7 
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CARDIOVASCULAR RISK IN HIV PATIENTS ON HAART DAD STUDY 
GROUP 
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PREVALENCE OF HIV IN DIFFERENT STATES IN INDIA -2007 
 
 
Fig-1 
 
 
 
 
 
 
South Indian States of Karnataka, Tamil Nadu ,Andhra Pradesh & 
Maharashtra constitutes 60% of the total cases . Manipur and Nagaland 
accounts for  the maximum prevalence of HIV infection  in India2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD-4  CELL COUNT  AMONG  HAART AND NON HAART 
GROUPS 
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SEVERE LIPOATROPHY OF FACE IN A PATIENT WITH AIDS 
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